Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)

    NEXT STORY
    Roche affiche une très bonne performance au premier semestre 2019 – prévisions pour l’année révisées à la hausse
    PREV STORY
    The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Oral Proteins and Peptides Market, 2030

    Dublin, May 16, 2018 (GLOBE NEWSWIRE) -- The "Oral Proteins and Peptides Market (3rd ...

    author_avatar
    NASDAQ Market News

    NexTech Launches Groundbreaking AR Human Hologram Marketing Platform “Genie in a Bottle” for “TruLyfe” Supplement Line

    author_avatar
    NASDAQ Market News

    Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    author_avatar
    NASDAQ Market News